Tag: innovation

News Highlights:

Suominen Corporation’s stock exchange release on June 8, 2026, at 10:30 a.m. (EEST)

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido^®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

SAN FRANCISCO, June 07, 2026 (GLOBE NEWSWIRE) -- On May 12, the Science x AI Summit 2026 held in Silicon Valley brought together numerous scientists, AI researchers, and industry institutions. Lim Meng Hoong, founder of MengHoong Intelligent Investment Academy, was invited to participate in the summit and engaged in discussions on the long-term impact of AI on scientific research systems and industrial structures. Unlike previous discussions centered on commercial applications, the summit this year placed greater emphasis on “how AI can drive scientific breakthroughs” and continued to advance international discussions around AI for Science.